Investigational drug · Phase 3
Rituxumab
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "Rituxumab"
First trial start
2021
Feb 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rituxumab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diffuse Large B-cell Lymphoma
- DLBCL - Diffuse Large B Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Rituxumab" as an intervention, largest first.
- A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04408638 · 270 participants (planned) · Start Feb 23, 2021 · Primary completion Mar 31, 2028
Drug: Obinutuzumab; Glofitamab and 4 more · For: Diffuse Large B-cell Lymphoma
Sites: Birmingham, Alabama; Fresno, California; Jacksonville, Florida · 63 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03677141 · 117 participants · Start Mar 8, 2019 · Primary completion Oct 12, 2023
Drug: Mosunetuzumab; Polatuzumab Vedotin and 6 more · For: B-cell Non-Hodgkin Lymphoma
Sites: Birmingham, Alabama; Gilbert, Arizona; La Jolla, California · 41 sites in all
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaPivotal-lookingRecruiting
Sinocelltech Ltd.Industry
NCT07570823 · 101 participants (planned) · Start Jun 4, 2026 · Primary completion Nov 2027
Drug: SCTB35 injection; Rituxumab and 2 more · For: DLBCL - Diffuse Large B Cell Lymphoma
Sites: Beijing, China
- Rituximab Plus Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's LymphomaStatus unknown
Lymphoma Trials OfficeAcademic, hospital or other
NCT00031902 · Start Oct 2001
Drug: bleomycin sulfate; rituximab and 2 more · For: Lymphoma
Sites: London, United Kingdom · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Anti-CD20 Disrupts Meningeal B-Cell Aggregates in a Model of Secondary Progressive Multiple Sclerosis.
Roodselaar J, Zhou Y, Leppert D, et al. · Neurol Neuroimmunol Neuroinflamm 2021
- Recurrent schilder's disease.
Dunn-Pirio AM, Eckstein C · Mult Scler Relat Disord 2018
- Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Federico M, Caballero Barrigón MD, Marcheselli L, et al. · Lancet Haematol 2018
- Clinical review of pulmonary manifestations of IgG4-related disease.
Campbell SN, Rubio E, Loschner AL · Ann Am Thorac Soc 2014
- Update on the management of chronic eczema: new approaches and emerging treatment options.
Walling HW, Swick BL · Clin Cosmet Investig Dermatol 2010
- A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD, Emmanouilides C, Benson DM, et al. · Clin Cancer Res 2006
Also in development for Diffuse Large B-cell Lymphoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- BirelentinibDZD8586Phase 37 trials
Dizal Pharmaceuticals · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Immune Thrombocytopenia (ITP)
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- BL-M08D1Phase 26 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Solid Tumors, Gastrointestinal Tumors, Diffuse Large B-Cell Lymphoma
- GNC-038Phase 24 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
- and oxaliplatinPhase 22 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
- and prednisonePhase 22 trials
Genmab · Follicular Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.